Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis
- PMID: 12112491
- DOI: 10.1002/hec.678
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis
Abstract
Economic evaluation is often seen as a branch of health economics divorced from mainstream econometric techniques. Instead, it is perceived as relying on statistical methods for clinical trials. Furthermore, the statistic of interest in cost-effectiveness analysis, the incremental cost-effectiveness ratio is not amenable to regression-based methods, hence the traditional reliance on comparing aggregate measures across the arms of a clinical trial. In this paper, we explore the potential for health economists undertaking cost-effectiveness analysis to exploit the plethora of established econometric techniques through the use of the net-benefit framework - a recently suggested reformulation of the cost-effectiveness problem that avoids the reliance on cost-effectiveness ratios and their associated statistical problems. This allows the formulation of the cost-effectiveness problem within a standard regression type framework. We provide an example with empirical data to illustrate how a regression type framework can enhance the net-benefit method. We go on to suggest that practical advantages of the net-benefit regression approach include being able to use established econometric techniques, adjust for imperfect randomisation, and identify important subgroups in order to estimate the marginal cost-effectiveness of an intervention.
Copyright 2002 John Wiley & Sons, Ltd.
Similar articles
-
Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.Stat Methods Med Res. 2002 Dec;11(6):455-68. doi: 10.1191/0962280202sm304ra. Stat Methods Med Res. 2002. PMID: 12516984
-
Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'.Health Econ. 1997 Sep-Oct;6(5):491-5. doi: 10.1002/(sici)1099-1050(199709)6:5<491::aid-hec293>3.0.co;2-r. Health Econ. 1997. PMID: 9353649
-
Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial.Eur J Gastroenterol Hepatol. 2004 Jun;16(6):543-9. doi: 10.1097/00042737-200406000-00006. Eur J Gastroenterol Hepatol. 2004. PMID: 15167155 Review.
-
A note on confidence intervals in cost-effectiveness analysis.Int J Technol Assess Health Care. 1998 Summer;14(3):467-71. doi: 10.1017/s0266462300011442. Int J Technol Assess Health Care. 1998. PMID: 9780533
-
Generalisability in economic evaluation studies in healthcare: a review and case studies.Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490. Health Technol Assess. 2004. PMID: 15544708 Review.
Cited by
-
Assessing the effectiveness and cost effectiveness of subcutaneous nerve stimulation in patients with predominant back pain due to failed back surgery syndrome (SubQStim study): study protocol for a multicenter randomized controlled trial.Trials. 2013 Jun 25;14:189. doi: 10.1186/1745-6215-14-189. Trials. 2013. PMID: 23799929 Free PMC article. Clinical Trial.
-
Moving from efficacy to effectiveness trials in prevention research.Behav Res Ther. 2011 Jan;49(1):32-41. doi: 10.1016/j.brat.2010.10.008. Epub 2010 Nov 2. Behav Res Ther. 2011. PMID: 21092935 Free PMC article.
-
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.Clinicoecon Outcomes Res. 2010;2:75-85. doi: 10.2147/ceor.s10835. Epub 2010 Jul 1. Clinicoecon Outcomes Res. 2010. PMID: 21935316 Free PMC article.
-
DO IT Trial: vitamin D Outcomes and Interventions in Toddlers - a TARGet Kids! randomized controlled trial.BMC Pediatr. 2014 Feb 8;14:37. doi: 10.1186/1471-2431-14-37. BMC Pediatr. 2014. PMID: 24506910 Free PMC article. Clinical Trial.
-
Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.Pharmacoeconomics. 2009;27(1):69-80. doi: 10.2165/00019053-200927010-00007. Pharmacoeconomics. 2009. PMID: 19178125
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical